[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488540":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":44,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"University Hospital, Geneva","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stereotactic radiosurgery group",null,"Patients with unilateral Vestibular Schwannoma treated with stereotactic radiosurgery, as proposed by the institution's skull base tumor board independently of the study.",[13],"Radiation: Stereotactic radiosurgery",{"label":15,"type":10,"description":16,"interventionNames":10},"Wait and scan group","Patients with unilateral Vestibular Schwannoma followed with an MRI-based observation strategy, as proposed by the institution's skull base tumor board independently of the study.",[18],{"type":19,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"RADIATION","Stereotactic radiosurgery",[9],[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Pascal Senn","CONTACT","0223728244","pascal.senn@hcuge.ch",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Service d'ORL et Chirurge cervico-faciale, Hopitaux Universitaires de Genève","RECRUITING","Geneva","1205","Switzerland","CH",{"type":37,"coordinates":38},"Point",[39,40],6.14569,46.20222,{"lat":40,"lon":39},[43],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},{"type":45,"investigatorFullName":24,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Chairman of the Service of Otorhinolaryngology-Head and Neck Surgery, Department of clinical neurosciences, Geneva University Hospitals","100488540","radiosurgery-induced-ototoxicity-in-patients-treated-for-a-vestibular-schwannoma-100488540",false,"NCT05641441","Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma","Inclusion Criteria:\n\n* Aged 18 years or above\n* Patients with unilateral VS treated either with SRS or MRI-based observation strategy, as proposed by the institution's skull base tumor board independently of the study\n* Patients willing to take part in the study and give their informed consent\n\nExclusion Criteria:\n\n* Previous surgical or radiation therapy for VS (including SRS)\n* Patients diagnosed with neurofibromatosis type II\n* Preexisting profound hearing loss, with a pure tone average (PTA) \\>90 and word recognition score (WRS) \\\u003C10%, upon initial assessment\n* Previous middle ear surgery of the affected ear\n* Concurrent treatment with other experimental drugs","ALL","18 Years",{"count":56,"type":57},258,"ESTIMATED","OBSERVATIONAL","The investigators aim to study the impact of stereotactic radiosurgery, for the treatment of vestibular Schwannoma, on the cochlear, vestibular, gustatory, and facial nerve functions and compare it with a conservatively treated group. The predictive value of radiological tumor characteristics on hearing preservation and vestibular function will be also evaluated.\n\nAdditionally, the investigators will invite patients with vestibular Schwannoma to fill out questionnaires to assess their quality of life.",[61,62],"Vestibular Schwannoma","Ototoxicity",[64,62,61,65,66],"Radiosurgery","Hearing loss","Quality of Life","2025-01-09",{"date":69,"type":70},"2025-01-13","ACTUAL",{"date":72,"type":70},"2023-01-24",{"date":74,"type":57},"2030-11-15",{"name":5,"class":6},1]